DexCom, Inc. (DXCM) FCF Payout Ratio: N/A
The FCF payout ratio for DexCom, Inc. (DXCM) is N/A.
DXCM FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
Payout Ratio Comparison
FCF Payout Ratio
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
4.84%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $1.08B | $0 | 0.0% |
| 2024 | $630.70M | $0 | 0.0% |
| 2023 | $511.90M | $0 | 0.0% |
| 2022 | $304.70M | $0 | 0.0% |
| 2021 | $53.30M | $0 | 0.0% |
| 2020 | $276.60M | $0 | 0.0% |
| 2019 | $134.50M | $0 | 0.0% |
| 2018 | $56.10M | $0 | 0.0% |
| 2017 | $26.00M | $0 | 0.0% |
| 2016 | $0.50M | $0 | 0.0% |
| 2015 | $15.70M | $0 | 0.0% |
| 2014 | $7.40M | $0 | 0.0% |
| 2013 | ($5.50M) | $0 | N/A (Loss) |
| 2012 | ($42.60M) | $0 | N/A (Loss) |
| 2011 | ($38.13M) | $0 | N/A (Loss) |
| 2010 | ($49.54M) | $0 | N/A (Loss) |
| 2009 | ($42.38M) | $0 | N/A (Loss) |
| 2008 | ($39.94M) | $0 | N/A (Loss) |
| 2007 | ($36.65M) | $0 | N/A (Loss) |
| 2006 | ($47.09M) | $0 | N/A (Loss) |
| 2005 | ($27.23M) | $0 | N/A (Loss) |
| 2004 | ($14.19M) | $0 | N/A (Loss) |
| 2003 | ($9.87M) | $0 | N/A (Loss) |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
DexCom, Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach